Litcius/Paper detail

Primary cardioprotection with dexrazoxane in patients with childhood cancer who are expected to receive anthracyclines: recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group

Esmée C. de Baat, Elvira C van Dalen, Renée L. Mulder, Melissa M. Hudson, Matthew J. Ehrhardt, Frederike K. Engels, Elizabeth A. M. Feijen, Heynric B. Grotenhuis, Jan M. Leerink, Livia Kapusta, Gertjan J.L. Kaspers, Remy Merkx, Luc Mertens, Roderick Skinner, Wim J. E. Tissing, Florent de Vathaire, Paul C. Nathan, Leontien C.M. Kremer, Annelies M. C. Mavinkurve‐Groothuis, Saro H. Armenian

2022The Lancet Child & Adolescent Health71 citationsDOIOpen Access PDF

Topics & Concepts

DexrazoxaneCardiotoxicityMedicineAnthracyclineGuidelineCancerHarmonizationCumulative doseDoxorubicinOncologyIntensive care medicineBreast cancerInternal medicineChemotherapyPathologyPhysicsAcousticsChemotherapy-induced cardiotoxicity and mitigationChildhood Cancer Survivors' Quality of LifeCancer-related cognitive impairment studies